Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.

Biomolecules - 12 Oct 2025

Ekyalongo Richy, Yamaoka Toshimitsu, Tsurutani Junji

Abstract excerpt

Alterations in the human epidermal growth factor receptor 2 (HER2) gene are well-recognized oncogenic drivers and therapeutic targets in non-small cell lung cancer (NSCLC). The first anti-HER2 inhibitor, trastuzumab-deruxtecan, was approved for previously treated advanced NSCLC with HER2 mutations, which accounts for 2-4% of NSCLC. The first anti-HER2 antibody, trastuzumab, was approved for HER2-positive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Erb-b2 Receptor Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to ERBB2 gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41154672
DOI: 10.3390/biom15101443
PMCID: PMC12562509

Genes

EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.PMID 41154672Read ↗

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.Semantic proximity Read ↗

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.Semantic proximity Read ↗

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging TherapiesSemantic proximity Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

The development of Zongertinib for HER2-mutant NSCLCSemantic proximity Read ↗

Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.Semantic proximity Read ↗

Targeting HER2 in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.